Page last updated: 2024-12-05

dibutyl phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dibutyl phosphate (DBP) is an organophosphate compound that is commonly used as a plasticizer. It is a colorless, viscous liquid that is soluble in organic solvents but only slightly soluble in water. DBP is synthesized by the reaction of phosphoric acid with butanol. It is used in a wide range of applications, including plastics, resins, and lubricants. DBP is also used in the production of pesticides and herbicides. However, DBP is a potential environmental and health hazard. It is toxic to aquatic organisms and can bioaccumulate in the food chain. DBP has also been shown to have endocrine disrupting effects in animals. There is ongoing research into the environmental and health effects of DBP, including its potential for endocrine disruption, its persistence in the environment, and its bioaccumulation in aquatic organisms. DBP is studied to understand its potential risks to human health and the environment, to develop safer alternatives, and to develop methods for its remediation. DBP is an important compound in the chemical industry, but it is also a potential environmental and health hazard. More research is needed to fully understand its risks and to develop safer alternatives.'

di-n-butylphosphoric acid: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7881
CHEMBL ID3187678
CHEBI ID166473
SCHEMBL ID26559
MeSH IDM0179106

Synonyms (46)

Synonym
107-66-4
AKOS009029141
CHEBI:166473
phosphoric acid, dibutyl ester
ai3-07849
dibutyl hydrogen phosphate
dp 4 (coupling agent)
dibutyl acid phosphate
di-n-butyl phosphate
brn 0607224
di-n-butyl hydrogen phosphate
hsdb 2513
einecs 203-509-8
dibutyl phosphate
di-n-butylphosphoric acid
19069-28-4
nsc-289390
nsc289390
NCGC00164273-01
72283-56-8
P0260
phosphoric acid dibutyl ester
P0267
NCGC00164273-02
4-01-00-01530 (beilstein handbook reference)
unii-0072nn74tn
0072nn74tn ,
ec 203-509-8
tox21_301186
dtxsid3040728 ,
cas-107-66-4
NCGC00255084-01
dtxcid1020728
FT-0631599
dibutyl phosphate [hsdb]
SCHEMBL26559
dibutylphosphate
CHEMBL3187678
J-001997
dibutyl phosphate, >=97.0% (t)
mfcd00015245
phosphoric acid di-n-butyl ester
di-n-butylphosphate
Q20963648
CS-0113589
F71269

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Furthermore, a nonlinear dose-response relationship was found between urinary BDCIPP concentration and cognitive decline."( Association between organophosphorus flame retardants exposure and cognitive impairment among elderly population in southern China.
Chen, X; Du, S; Huang, X; Lin, X; Liu, J; Liu, W; Lu, S; Shen, J; Xiao, L; Zhang, D; Zhao, Y, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dialkyl phosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen nuclear receptor alphaHomo sapiens (human)Potency48.06900.000229.305416,493.5996AID743075; AID743077; AID743079
Histone H2A.xCricetulus griseus (Chinese hamster)Potency126.79300.039147.5451146.8240AID1224845
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (15.00)18.2507
2000's2 (10.00)29.6817
2010's12 (60.00)24.3611
2020's3 (15.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.69 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index5.38 (4.65)
Search Engine Demand Index46.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]